OKYO Pharma (OKYO) Common Equity (2021 - 2025)

OKYO Pharma (OKYO) has 5 years of Common Equity data on file, last reported at -$3.4 million in Q3 2025.

• Common Equity for Q3 2025 came in at -$3.4 million, up 52.73% year-over-year; the trailing twelve-month figure through Sep 2025 was -$3.4 million (up 52.73% YoY), and the FY2025 annual result was -$5.5 million, up 5.61% from the prior year.
• Common Equity advanced to -$3.4 million in Q3 2025 per OKYO's latest filing, from -$5.5 million in the prior quarter.
• Over five years, Common Equity peaked at $5.3 million in Q1 2021 and troughed at -$7.2 million in Q3 2024.
• A 5-year average of -$2.7 million and a median of -$4.5 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 186.36% in 2024, then soared 52.73% in 2025.
• A 5-year view of Common Equity shows it stood at $5.3 million in 2021, then plunged by 44.59% to $2.9 million in 2022, then plunged by 301.48% to -$5.9 million in 2023, then dropped by 21.68% to -$7.2 million in 2024, then soared by 52.73% to -$3.4 million in 2025.
• Business Quant data shows OKYO's Common Equity at -$3.4 million in Q3 2025, -$5.5 million in Q1 2025, and -$7.2 million in Q3 2024.